Skip to main content

Table 3 Change in variables in obese with relative GHD children treated with GH vs control group for 6 months

From: Effects of recombinant human growth hormone administration on cardiovascular risk factors in obese children with relative growth hormone deficiency

Variable

rhGH group (n = 23)

control group (n = 20)

P value

BMI SDS

2.32(0.85)

2.80(0.61)

0.041*

IGF-1(ng/ml)

702.91(246.03)

348.3(131.93)

< 0.001*

TC(mmol/L)

4.14(0.73)

4.29(0.99)

0.584

HDL-C (mmol/L)

1.45(0.40)

1.19(0.23)

0.016*#

LDL-C (mmol/L)

2.20(0.45)

2.63(0.76)

0.027*

TG(mmol/L)

1.02(0.38)

1.18(0.45)

0.261#

ALT(U/L)

16.70(6.72)

45.20(46.62)

0.002*#

AST(U/L)

21.26(5.72)

32.3(17.68)

0.006*#

Insulin(uIU/mL)

27.06(10.99)

23.26(9.78)

0.241

FBG(mmol/L)

5.46(0.41)

5.25(0.48)

0.123

HOMA-IR

6.62(2.86)

5.44(2.38)

0.152

HbA1c (%)

5.61(0.34)

5.64(0.30)

0.79

  1. BMI SDS body mass index standard deviation scores, IGF-1 Insulin-like growth factor 1, TC total cholesterol, HDL-C High density lipoprotein cholesterol, LDL-C Low density lipoprotein cholesterol, TG triglycerides, ALT alanine aminotransferase, AST aspartate aminotransferase, FBG fasting blood glucose, HOMA-IR homeostasis model assessment of IR, HbA1c Glycosylated haemoglobin
  2. *P<0.05
  3. #P value reported for log transformed values, but values in the table represent a back transformation to the original